Insider Trading Alert - ENDP, GT And TIBX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 7, 2014, 70 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $646.00 to $62,506,298.61.

Highlighted Stocks Traded by Insiders:

Endo International (ENDP) - FREE Research Report

Higgins Arthur J, who is Director at Endo International, bought 3,500 shares at $65.65 on Aug. 7, 2014. Following this transaction, the Director owned 8,827 shares meaning that the stake was boosted by 65.7% with the 3,500-share transaction.

The shares most recently traded at $62.06, down $3.59, or 5.78% since the insider transaction. Historical insider transactions for Endo International go as follows:

  • 12-Week # shares bought: 5,478
  • 12-Week # shares sold: 15,592
  • 24-Week # shares bought: 5,478
  • 24-Week # shares sold: 15,592

The average volume for Endo International has been 1.8 million shares per day over the past 30 days. Endo International has a market cap of $9.5 billion and is part of the health care sector and drugs industry. Shares are down 8.58% year-to-date as of the close of trading on Thursday.

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. Currently, there are 9 analysts who rate Endo International a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENDP - FREE

TheStreet Quant Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full Endo International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

3 Biotech Stocks on Readers' Minds